Intrinsic value of MyoKardia - MYOK

Previous Close

$54.07

  Intrinsic Value

$25.60

stock screener

  Rating & Target

str. sell

-53%

Previous close

$54.07

 
Intrinsic value

$25.60

 
Up/down potential

-53%

 
Rating

str. sell

We calculate the intrinsic value of MYOK stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 2.1

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  36
  56
  83
  121
  170
  234
  314
  413
  531
  671
  833
  1,018
  1,227
  1,460
  1,717
  1,997
  2,300
  2,626
  2,974
  3,344
  3,735
  4,146
  4,578
  5,030
  5,503
  5,995
  6,508
  7,041
  7,596
  8,173
Variable operating expenses, $m
  49
  75
  112
  163
  230
  316
  424
  556
  716
  904
  1,122
  1,372
  1,654
  1,968
  2,314
  2,692
  3,101
  3,540
  4,010
  4,508
  5,035
  5,589
  6,172
  6,781
  7,418
  8,081
  8,773
  9,492
  10,240
  11,017
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  49
  75
  112
  163
  230
  316
  424
  556
  716
  904
  1,122
  1,372
  1,654
  1,968
  2,314
  2,692
  3,101
  3,540
  4,010
  4,508
  5,035
  5,589
  6,172
  6,781
  7,418
  8,081
  8,773
  9,492
  10,240
  11,017
Operating income, $m
  -13
  -19
  -29
  -42
  -59
  -81
  -109
  -144
  -185
  -233
  -290
  -354
  -427
  -508
  -597
  -695
  -801
  -914
  -1,035
  -1,164
  -1,300
  -1,443
  -1,593
  -1,751
  -1,915
  -2,086
  -2,265
  -2,450
  -2,643
  -2,844
EBITDA, $m
  -12
  -18
  -27
  -39
  -55
  -75
  -101
  -133
  -171
  -216
  -268
  -328
  -396
  -471
  -553
  -644
  -742
  -847
  -959
  -1,078
  -1,204
  -1,337
  -1,476
  -1,622
  -1,774
  -1,933
  -2,098
  -2,270
  -2,449
  -2,635
Interest expense (income), $m
  0
  0
  2
  4
  7
  12
  18
  26
  36
  48
  62
  79
  99
  122
  147
  176
  207
  241
  279
  318
  361
  406
  454
  504
  557
  613
  670
  731
  793
  859
  926
Earnings before tax, $m
  -13
  -21
  -33
  -49
  -71
  -99
  -135
  -179
  -232
  -295
  -369
  -453
  -549
  -655
  -773
  -902
  -1,042
  -1,193
  -1,354
  -1,525
  -1,706
  -1,897
  -2,098
  -2,308
  -2,527
  -2,757
  -2,995
  -3,244
  -3,502
  -3,771
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -13
  -21
  -33
  -49
  -71
  -99
  -135
  -179
  -232
  -295
  -369
  -453
  -549
  -655
  -773
  -902
  -1,042
  -1,193
  -1,354
  -1,525
  -1,706
  -1,897
  -2,098
  -2,308
  -2,527
  -2,757
  -2,995
  -3,244
  -3,502
  -3,771

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  122
  189
  283
  411
  579
  796
  1,069
  1,403
  1,806
  2,281
  2,832
  3,463
  4,174
  4,966
  5,839
  6,792
  7,824
  8,933
  10,117
  11,375
  12,704
  14,104
  15,573
  17,110
  18,717
  20,391
  22,136
  23,950
  25,837
  27,799
Adjusted assets (=assets-cash), $m
  122
  189
  283
  411
  579
  796
  1,069
  1,403
  1,806
  2,281
  2,832
  3,463
  4,174
  4,966
  5,839
  6,792
  7,824
  8,933
  10,117
  11,375
  12,704
  14,104
  15,573
  17,110
  18,717
  20,391
  22,136
  23,950
  25,837
  27,799
Revenue / Adjusted assets
  0.295
  0.296
  0.293
  0.294
  0.294
  0.294
  0.294
  0.294
  0.294
  0.294
  0.294
  0.294
  0.294
  0.294
  0.294
  0.294
  0.294
  0.294
  0.294
  0.294
  0.294
  0.294
  0.294
  0.294
  0.294
  0.294
  0.294
  0.294
  0.294
  0.294
Average production assets, $m
  5
  7
  11
  15
  22
  30
  40
  53
  68
  86
  107
  130
  157
  187
  220
  256
  294
  336
  381
  428
  478
  531
  586
  644
  704
  767
  833
  901
  972
  1,046
Working capital, $m
  -77
  -119
  -177
  -257
  -363
  -499
  -670
  -880
  -1,132
  -1,430
  -1,775
  -2,170
  -2,616
  -3,113
  -3,660
  -4,257
  -4,904
  -5,599
  -6,341
  -7,130
  -7,963
  -8,840
  -9,761
  -10,725
  -11,732
  -12,782
  -13,875
  -15,012
  -16,195
  -17,424
Total debt, $m
  29
  74
  136
  221
  334
  478
  660
  883
  1,151
  1,467
  1,834
  2,254
  2,728
  3,255
  3,837
  4,472
  5,159
  5,897
  6,686
  7,523
  8,409
  9,341
  10,319
  11,343
  12,413
  13,529
  14,690
  15,899
  17,156
  18,462
Total liabilities, $m
  82
  126
  188
  273
  386
  530
  712
  935
  1,203
  1,519
  1,886
  2,306
  2,780
  3,307
  3,889
  4,524
  5,211
  5,949
  6,738
  7,575
  8,461
  9,393
  10,371
  11,396
  12,465
  13,581
  14,742
  15,951
  17,208
  18,514
Total equity, $m
  41
  63
  94
  137
  193
  266
  357
  469
  603
  762
  946
  1,157
  1,394
  1,659
  1,950
  2,269
  2,613
  2,984
  3,379
  3,799
  4,243
  4,711
  5,201
  5,715
  6,251
  6,811
  7,393
  7,999
  8,630
  9,285
Total liabilities and equity, $m
  123
  189
  282
  410
  579
  796
  1,069
  1,404
  1,806
  2,281
  2,832
  3,463
  4,174
  4,966
  5,839
  6,793
  7,824
  8,933
  10,117
  11,374
  12,704
  14,104
  15,572
  17,111
  18,716
  20,392
  22,135
  23,950
  25,838
  27,799
Debt-to-equity ratio
  0.720
  1.170
  1.440
  1.610
  1.720
  1.800
  1.850
  1.880
  1.910
  1.930
  1.940
  1.950
  1.960
  1.960
  1.970
  1.970
  1.970
  1.980
  1.980
  1.980
  1.980
  1.980
  1.980
  1.980
  1.990
  1.990
  1.990
  1.990
  1.990
  1.990
Adjusted equity ratio
  0.334
  0.334
  0.334
  0.334
  0.334
  0.334
  0.334
  0.334
  0.334
  0.334
  0.334
  0.334
  0.334
  0.334
  0.334
  0.334
  0.334
  0.334
  0.334
  0.334
  0.334
  0.334
  0.334
  0.334
  0.334
  0.334
  0.334
  0.334
  0.334
  0.334

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -13
  -21
  -33
  -49
  -71
  -99
  -135
  -179
  -232
  -295
  -369
  -453
  -549
  -655
  -773
  -902
  -1,042
  -1,193
  -1,354
  -1,525
  -1,706
  -1,897
  -2,098
  -2,308
  -2,527
  -2,757
  -2,995
  -3,244
  -3,502
  -3,771
Depreciation, amort., depletion, $m
  1
  1
  2
  3
  4
  6
  8
  11
  14
  17
  21
  26
  31
  37
  44
  51
  59
  67
  76
  86
  96
  106
  117
  129
  141
  153
  167
  180
  194
  209
Funds from operations, $m
  -12
  -20
  -31
  -46
  -67
  -93
  -127
  -169
  -219
  -278
  -348
  -427
  -517
  -618
  -729
  -851
  -983
  -1,125
  -1,277
  -1,439
  -1,610
  -1,791
  -1,980
  -2,179
  -2,387
  -2,603
  -2,829
  -3,063
  -3,308
  -3,561
Change in working capital, $m
  -29
  -42
  -59
  -80
  -106
  -136
  -171
  -210
  -252
  -298
  -346
  -395
  -446
  -497
  -547
  -597
  -647
  -695
  -742
  -788
  -833
  -877
  -921
  -964
  -1,007
  -1,050
  -1,093
  -1,137
  -1,183
  -1,229
Cash from operations, $m
  17
  22
  28
  34
  39
  43
  44
  41
  33
  19
  -2
  -32
  -72
  -121
  -182
  -254
  -336
  -430
  -535
  -651
  -777
  -914
  -1,060
  -1,215
  -1,380
  -1,553
  -1,735
  -1,926
  -2,125
  -2,332
Maintenance CAPEX, $m
  -1
  -1
  -1
  -2
  -3
  -4
  -6
  -8
  -11
  -14
  -17
  -21
  -26
  -31
  -37
  -44
  -51
  -59
  -67
  -76
  -86
  -96
  -106
  -117
  -129
  -141
  -153
  -167
  -180
  -194
New CAPEX, $m
  -2
  -3
  -4
  -5
  -6
  -8
  -10
  -13
  -15
  -18
  -21
  -24
  -27
  -30
  -33
  -36
  -39
  -42
  -45
  -47
  -50
  -53
  -55
  -58
  -60
  -63
  -66
  -68
  -71
  -74
Cash from investing activities, $m
  -3
  -4
  -5
  -7
  -9
  -12
  -16
  -21
  -26
  -32
  -38
  -45
  -53
  -61
  -70
  -80
  -90
  -101
  -112
  -123
  -136
  -149
  -161
  -175
  -189
  -204
  -219
  -235
  -251
  -268
Free cash flow, $m
  15
  19
  23
  27
  29
  30
  27
  20
  8
  -12
  -40
  -77
  -124
  -183
  -252
  -333
  -426
  -531
  -647
  -774
  -913
  -1,062
  -1,221
  -1,390
  -1,569
  -1,757
  -1,955
  -2,161
  -2,376
  -2,600
Issuance/(repayment) of debt, $m
  29
  44
  62
  85
  112
  145
  182
  223
  268
  316
  367
  420
  474
  528
  582
  635
  687
  739
  789
  838
  885
  932
  978
  1,024
  1,070
  1,115
  1,162
  1,209
  1,257
  1,306
Issuance/(repurchase) of shares, $m
  27
  43
  64
  92
  128
  172
  226
  291
  367
  454
  553
  664
  786
  920
  1,065
  1,220
  1,387
  1,563
  1,749
  1,945
  2,150
  2,365
  2,588
  2,821
  3,064
  3,316
  3,578
  3,850
  4,132
  4,426
Cash from financing (excl. dividends), $m  
  56
  87
  126
  177
  240
  317
  408
  514
  635
  770
  920
  1,084
  1,260
  1,448
  1,647
  1,855
  2,074
  2,302
  2,538
  2,783
  3,035
  3,297
  3,566
  3,845
  4,134
  4,431
  4,740
  5,059
  5,389
  5,732
Total cash flow (excl. dividends), $m
  71
  107
  150
  204
  269
  347
  435
  534
  643
  759
  880
  1,007
  1,135
  1,265
  1,394
  1,522
  1,648
  1,771
  1,891
  2,008
  2,123
  2,235
  2,346
  2,455
  2,565
  2,674
  2,785
  2,898
  3,013
  3,131
Retained Cash Flow (-), $m
  -27
  -43
  -64
  -92
  -128
  -172
  -226
  -291
  -367
  -454
  -553
  -664
  -786
  -920
  -1,065
  -1,220
  -1,387
  -1,563
  -1,749
  -1,945
  -2,150
  -2,365
  -2,588
  -2,821
  -3,064
  -3,316
  -3,578
  -3,850
  -4,132
  -4,426
Prev. year cash balance distribution, $m
  205
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  249
  63
  85
  112
  142
  175
  209
  243
  276
  304
  327
  343
  349
  345
  329
  301
  261
  208
  142
  63
  -27
  -130
  -243
  -366
  -499
  -642
  -793
  -952
  -1,119
  -1,294
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  239
  58
  74
  92
  110
  127
  141
  152
  158
  160
  155
  146
  133
  116
  97
  77
  57
  38
  22
  8
  -3
  -11
  -16
  -19
  -19
  -19
  -17
  -15
  -12
  -10
Current shareholders' claim on cash, %
  89.9
  80.7
  72.8
  65.9
  59.9
  54.7
  50.1
  46.1
  42.5
  39.3
  36.5
  33.9
  31.6
  29.5
  27.6
  25.9
  24.3
  22.8
  21.5
  20.2
  19.1
  18.0
  17.0
  16.1
  15.2
  14.4
  13.6
  12.9
  12.2
  11.6

MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. The Company has used its precision medicine platform to generate an initial pipeline of over four therapeutic programs for the chronic treatment of two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Additionally, the Company has three preclinical programs, HCM-2, DCM-2 and LUS-1. Its lead product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM.

FINANCIAL RATIOS  of  MyoKardia (MYOK)

Valuation Ratios
P/E Ratio -130.7
Price to Sales 43.6
Price to Book 11.7
Price to Tangible Book
Price to Cash Flow -80.9
Price to Free Cash Flow -77.2
Growth Rates
Sales Growth Rate 178.6%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 0%
Cap. Spend. - 3 Yr. Gr. Rate 0%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -8.2%
Ret/ On Assets - 3 Yr. Avg. -33.9%
Return On Total Capital -10.9%
Ret/ On T. Cap. - 3 Yr. Avg. -84.4%
Return On Equity -10.9%
Return On Equity - 3 Yr. Avg. -84.4%
Asset Turnover 0.2
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -30.8%
EBITDA Margin - 3 Yr. Avg. -151.5%
Operating Margin -35.9%
Oper. Margin - 3 Yr. Avg. -161.2%
Pre-Tax Margin -33.3%
Pre-Tax Margin - 3 Yr. Avg. -160.3%
Net Profit Margin -33.3%
Net Profit Margin - 3 Yr. Avg. -160.3%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

MYOK stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the MYOK stock intrinsic value calculation we used $22.5 million for the last fiscal year's total revenue generated by MyoKardia. The default revenue input number comes from 0001 income statement of MyoKardia. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our MYOK stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for MYOK is calculated based on our internal credit rating of MyoKardia, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of MyoKardia.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of MYOK stock the variable cost ratio is equal to 134.8%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for MYOK stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for MyoKardia.

Corporate tax rate of 27% is the nominal tax rate for MyoKardia. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the MYOK stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for MYOK are equal to 12.8%.

Life of production assets of 2.3 years is the average useful life of capital assets used in MyoKardia operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for MYOK is equal to -213.2%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $230.676 million for MyoKardia - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 39.733 million for MyoKardia is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of MyoKardia at the current share price and the inputted number of shares is $2.1 billion.

RELATED COMPANIES Price Int.Val. Rating
SEM Select Medical 19.21 90.59  str.buy
CAPR Capricor Thera 0.890 0.09  str.sell

COMPANY NEWS

▶ MyoKardia: 3Q Earnings Snapshot   [07:48PM  Associated Press]
▶ Big pharma leases almost 500,000 square feet for new research center   [Nov-01-18 10:23AM  American City Business Journals]
▶ Bears Are Doing an EKG Test on MyoKardia   [Oct-31-18 10:10AM  TheStreet.com]
▶ Health Care Digest: A small biotech goes head first, Gilead's lower tax rate and more   [Oct-29-18 10:17AM  American City Business Journals]
▶ MyoKardia to Host R&D Day on October 30, 2018   [Oct-22-18 08:30AM  GlobeNewswire]
▶ Health Care Digest: Genentech's neuro legacy, uBiome's haul, plus saving moms   [Sep-24-18 11:10AM  American City Business Journals]
▶ MyoKardia: 2Q Earnings Snapshot   [07:02PM  Associated Press]
▶ MyoKardia, Inc. to Host Earnings Call   [02:30PM  ACCESSWIRE]
▶ BofA Revives Myokardia With New Buy Rating   [Jul-10-18 02:06PM  Benzinga]
▶ Should You Buy MyoKardia Inc (NASDAQ:MYOK) At $50.55?   [May-18-18 07:07PM  Simply Wall St.]
▶ MyoKardia: 1Q Earnings Snapshot   [May-08-18 05:44PM  Associated Press]
▶ MyoKardia reports 4Q loss   [Mar-08-18 05:28PM  Associated Press]
▶ MyoKardia, Inc. to Host Earnings Call   [01:15PM  ACCESSWIRE]
▶ Earnings Preview For MyoKardia   [09:34AM  Benzinga]
▶ ETFs with exposure to MyoKardia, Inc. : December 26, 2017   [Dec-26-17 11:51AM  Capital Cube]
▶ Myokardia Inc (MYOK) Q3:17 Update At First Glance   [Nov-07-17 12:48PM  SmarterAnalyst]
▶ MyoKardia reports 3Q loss   [Nov-02-17 05:54PM  Associated Press]
▶ ETFs with exposure to MyoKardia, Inc. : October 10, 2017   [Oct-10-17 11:39AM  Capital Cube]
▶ MyoKardia Provides Update on MYK-491 Clinical Progress   [Sep-27-17 07:30AM  GlobeNewswire]
▶ [$$] Zinsli's Take: Biotech's Saviors Keep Up VCs' Hopes   [Aug-09-17 07:30AM  The Wall Street Journal]
▶ MyoKardia reports 2Q loss   [Aug-07-17 11:59PM  Associated Press]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.